Tirzepatide
STRIDES
Eli Lilly · Phase 2 · Terminated · Enrollment 204
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| A: Tirzepatide Monotherapy | n/r | n/r | n/r | n/r |
| B: Azelaprag once daily plus Tirzepatide | n/r | n/r | n/r | n/r |
| C: Azelaprag twice daily plus Tirzepatide | n/r | n/r | n/r | n/r |
| D: Azelaprag Monotherapy | n/r | n/r | n/r | n/r |
Not shown
- A: Tirzepatide Monotherapy: endpoint not reported
- B: Azelaprag once daily plus Tirzepatide: endpoint not reported
- C: Azelaprag twice daily plus Tirzepatide: endpoint not reported
- D: Azelaprag Monotherapy: endpoint not reported